Medicinal Chemistry, Monash Institute of Pharmaceutical Science, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia Drug Delivery, Disposition & Dynamics, Monash Institute of ...

The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may ...

Shah et al. developed another inhibitor of SIRT2 (RK-9123016), which also reduced the viability of human breast cancer cells via downregulated c-Myc expression. This drug was found to increase the ...

Thus, AMPK promotes p53 acetylation and exerts antioncogenic functions in HCC ... since it has fewer negative consequences than therapies that activate apoptosis (232, 233). c-Myc was shown to ...

In RAF-inhibitor resistant melanoma cells, we measured 143 proteomic/phenotypic entities under 89 perturbation conditions and predicted c-Myc as an effective therapeutic co-target with BRAF or MEK.